Bayer Animal Health in the news

Adivo GmbH and Bayer Animal Health GmbH are collaborating globally to develop therapeutic antibodies for veterinary medicine, focusing on innovative pet treatments.

The animal health market is expanding due to increased awareness of zoonotic diseases, technological advancements in treatments and diagnostics, and the growing trend of pet humanization.

Bayer is divesting its profitable Animal Health division to Elanco for 6.8 billion euros to reduce corporate debt.

Elanco, PetMed Express, and Tractor Supply settled a lawsuit alleging they blocked generic flea and tick medications from the market.

Elanco Animal Health Inc. published its 10-K report, highlighting its global market presence, diverse product portfolio, and strategic acquisitions while addressing regulatory hurdles and competitive pressures.

Elanco Animal Health's shares hit a 52-week high following better-than-expected Q4 2025 results and a strong 2026 revenue forecast.

Financial analysts are raising stock price targets for Elanco Animal Health due to strong growth expectations in the global veterinary pharmaceutical market.

Piper Sandler upgraded Elanco Animal Health to Overweight and raised its price target to $30.00 amid positive market sentiment.

Executives at Elanco purchased significant stock following financial reports showing strong margins but high volatility and revenue challenges.

Elanco Animal Health is implementing a major restructuring plan involving job cuts and facility closures to save $250 million annually by 2030.

Elanco Animal Health is experiencing a growth turnaround driven by new products and improved financial stability.

A judge dismissed federal monopoly claims against Elanco Animal Health over pet medication pricing but allowed state-level litigation to proceed.

A U.S. judge narrowed a consumer lawsuit alleging Elanco monopolized the flea and tick treatment market, but dismissed federal antitrust claims due to insufficient evidence of price-fixing.

The European Commission has approved Elanco's over £6 billion acquisition of Bayer Animal Health, making Elanco the second-largest animal health company globally.

Bayer is facing an antitrust lawsuit in the US over alleged anti-competitive practices by its former animal health division regarding flea and tick remedies, which Bayer denies.

Bayer divests its Animal Health business to Elanco Animal Health for $7.6 billion, including cash and Elanco shares.

Elanco has completed the acquisition of Bayer Animal Health to expand its digital sales capabilities and balance its pet and livestock portfolios.

Bayer completed the sale of its Animal Health business to Elanco Animal Health Incorporated.

Elanco Animal Health completed its nearly $7-billion acquisition of Bayer Animal Health, aiming for industry leadership and expanded product offerings in livestock and pet care.

Elanco acquired Bayer Animal Health for $6.89 billion, boosting its leadership in the animal health industry.